Home

Insights

PE

RPG Life Sciences Ltd P/E Ratio

RPG Life Sciences Ltd P/E Ratio

download
stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

0.3 K

stocks traded

Last Updated time: 14 Jul 9.00 AM

Image

RPG Life Sciences Ltd

NSE: RPGLIFE

PE

29.9

Last updated : 14 Jul 9.00 AM

Key Highlights

    The P/E Ratio of RPG Life Sciences Ltd is 29.9 as of 14 Jul 9.00 AM .a1#The P/E Ratio of RPG Life Sciences Ltd changed from 37.9 on March 2019 to 28.9 on March 2024 . This represents a CAGR of -4.42% over 6 years. a1#The Latest Trading Price of RPG Life Sciences Ltd is ₹ 1568 as of 12 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.7. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 35.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of RPG Life Sciences Ltd changed from ₹ 409.75 crore on March 2019 to ₹ 2530 crore on March 2024 . This represents a CAGR of 35.45% over 6 years. a1#The Revenue of RPG Life Sciences Ltd changed from ₹ 130.15 crore to ₹ 128.64 crore over 8 quarters. This represents a CAGR of -0.58% a1#The EBITDA of RPG Life Sciences Ltd changed from ₹ 29.06 crore to ₹ 22.37 crore over 8 quarters. This represents a CAGR of -12.26% a1#The Net Pr of RPG Life Sciences Ltd changed from ₹ 18.21 crore to ₹ 13.24 crore over 8 quarters. This represents a CAGR of -14.73% a1#The Dividend Payout of RPG Life Sciences Ltd changed from 39.73 % on March 2019 to 30.18 % on March 2024 . This represents a CAGR of -4.48% over 6 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of RPG Life Sciences Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of RPG Life Sciences Ltd

Period
Mar '1937.9
Mar '209.7
Mar '2116
Mar '2218
Mar '2317
Mar '2428.9

Company Fundamentals for RPG Life Sciences Ltd

Market Cap

2,593 Cr

EPS

52.5

P/E Ratio (TTM) *

29.9

P/B Ratio (TTM) *

6.9

Day’s High

1600.0

Day’s Low

1558.4

DTE *

0.0

ROE *

23.4

52 Week High

1740.0

52 Week Low

941.9

ROCE *

31.3

* All values are consolidated

Last Updated time: 14 Jul 9.00 AM

* All values are consolidated

Last Updated time: 14 Jul 9.00 AM

Image

RPG Life Sciences Ltd

NSE: RPGLIFE

PRICE

1568.1

-2.10 (-0.13%)

stock direction

Last updated : 12 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of RPG Life Sciences Ltd

Strength

2

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value of RPG Life Sciences Ltd

Market Value

2,593

Asset Value

214

11.1 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
RPG Life Sciences Ltd292,593
Sun Pharmaceuticals Industries Ltd37378,675
Cipla Ltd28122,093
Divis Laboratories Ltd75120,480
Zydus Lifesciences Ltd30118,217
Dr Reddys Laboratories Ltd20112,137

Key Valuation Metric of RPG Life Sciences Ltd

Earnings

87 Cr

29.9 X

PE Ratio

Market Cap

₹2593Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

87 Cr

29.9 X

PE Ratio

Market Cap

₹2593Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of RPG Life Sciences Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of RPG Life Sciences Ltd

Period
Mar '19410
Mar '20282
Mar '21640
Mar '22926
Mar '231151
Mar '242531

* All values are a in crore

×

Historical Revenue of RPG Life Sciences Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of RPG Life Sciences Ltd

Period
Jun '22130
Sep '22136
Dec '22131
Mar '23120
Jun '23150
Sep '23155
Dec '23156
Mar '24129

* All values are a in crore

×

Historical EBITDA of RPG Life Sciences Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of RPG Life Sciences Ltd

Period
Jun '2229
Sep '2231
Dec '2230
Mar '2318
Jun '2334
Sep '2339
Dec '2340
Mar '2422

* All values are a in crore

×

Historical Net Profit of RPG Life Sciences Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of RPG Life Sciences Ltd

Period
Jun '2218
Sep '2220
Dec '2219
Mar '2310
Jun '2322
Sep '2326
Dec '2326
Mar '2413

* All values are a in crore

×

Historical Dividend Payout of RPG Life Sciences Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of RPG Life Sciences Ltd

Period
Mar '1940
Mar '2025
Mar '2130
Mar '2231
Mar '2329
Mar '2430

* All values are a in %

About RPG Life Sciences Ltd

About RPG Life Sciences Ltd

    RPG Life Sciences, formerly Searle India Ltd, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat. RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology. New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 2009-10. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010. New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neo-life). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 2010-11. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets. The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-17. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. Urolife' catering to the urology therapy and Glodiance division catering to the Cosmetic Derma therapy in 2016-17. In 2017-18, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the post-transplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY'18. It retained leadership position in Mauritius, through anti-diabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space. During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, T-JAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and Aldactone-F was launched in FY'22.

RPG Life Sciences Ltd News Hub

News

RPG Life Sciences to announce Quarterly Result

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 19 July ...

Read more

13 Jul 202410:33

News

RPG Life Sciences to convene AGM

RPG Life Sciences announced that the Annual General Meeting (AGM) of the company will be h...

Read more

12 Jun 202413:44

News

Board of RPG Life Sciences recommends final dividend

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held...

Read more

02 May 202411:08

News

RPG Life Sciences to hold board meeting

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 30 April...

Read more

24 Apr 202410:29

News

RPG Life edges higher after ICRA upgrades LT rating to 'A+'

The credit rating agency has reaffirmed the company’s short-term rating at ‘ICRA] A1’. ICR...

Read more

06 Mar 202412:54

News

RPG Life Sciences to hold board meeting

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 1 Februa...

Read more

27 Jan 202414:29

Product Composition by Percentage (Revenue)

FAQs for PE of RPG Life Sciences Ltd

What is RPG Life Sciences Ltd current share price?

The current market price of RPG Life Sciences Ltd as of July 14, 2024 is ₹1568.10.

What is RPG Life Sciences Ltd's market cap?

RPG Life Sciences Ltd's market capitalisation stood at ₹2,593 Cr as of July 14, 2024

What are RPG Life Sciences Ltd's total net assets?

According to RPG Life Sciences Ltd's most recent financial filings, the company's net assets total ₹213.9 Cr.

Is RPG Life Sciences Ltd making a profit or loss?

RPG Life Sciences Ltd's net Profit as of July 14, 2024 is close to ₹87 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199